ACTUATE THERAPEUTICS

ACTU11 Dec 2024
Healthcare
$8.4
-0.01 (-0.72%)
Lowest Today
$8.3
Highest Today
$8.4
Today’s Open
$8.4
Prev. Close
$8.38
52 Week High
$10.16
52 Week Low
$5.51
To Invest in ACTUATE THERAPEUTICS

ACTUATE THERAPEUTICS

Healthcare
ACTU11 Dec 2024
-0.01 (-0.72%)
1M
3M
6M
1Y
5Y
Low
$8.3
Day’s Range
High
$8.4
8.3
52 Week Low
$5.51
52-Week Range
52 Week High
$10.16
5.51
1 Day
-
1 Week
-4.77%
1 month return
-6.68%
3 month return
+2.94%
6 month return
+3.45%
1 Year return
-
3 Years return
-
5 Years return
-
10 Years return
-
Fundamentals
Market Cap
152.89 mln
PB Ratio
0
PE Ratio
0
Enterprise Value
158.21 mln
Total Assets
3 mln
Volume

Fund house & investment objective

Company Information
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Organisation
ACTUATE THERAPEUTICS
Employees
11
Industry
Biotechnology
CEO
Mr. Daniel M. Schmitt
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step